Organ-Specific Recurrence or Metastatic Pattern of Breast Cancer according to Biological Subtypes and Clinical Characteristics
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose: We aimed to investigate organ-specific recurrence or the metastatic pattern of breast cancer according to biological subtypes and clinical characteristics. Methods: We retrospectively analyzed the medical records of 168 patients with recurrent breast cancer who were diagnosed between January 1, 2000 and April 30, 2017. Four biological subtypes were classified according to estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), and Ki-67 expression: luminal A, luminal B, HER2-enriched, and triple negative breast cancer (TNBC). To analyze recurrence patterns according to biological subtypes, we accessed clinical variables including age at diagnosis, TNM stage, type of surgery in the breast and axilla, histologic grade, nuclear grade, lymphatic, vascular, and neural invasion, Ki-67 expression and recurrence to distant organs. Results: The biological subtypes of recurrent breast cancer comprised the following luminal A (n=33, 19.6%), luminal B (n=95, 56.5%), HER2 enriched (n=19, 11.3%), and TNBC (n=21, 12.5%). Luminal A (7.7%) and B (6.5%) subtypes were associated with the increased rate of local recurrence compared to HER2-enriched (2.4%) and TNBC subtypes (1.8%) (p=0.005). The bone (53.6%) was the most common metastatic organ, followed by the lung (34.5%), liver (29.8%), brain (17.9%), and other visceral organ (7.7%). Bone metastasis was commonly observed in individuals with luminal B (63.2%), HER2-enriched (57.9%), and luminal A (42.4%) subtypes (p=0.005). Most liver metastases occur in individuals with luminal B (40.0%) and HER2-enriched subtypes (31.6%) (p=0.002). Conclusion: Luminal B subtype was commonly observed in individuals with recurrent breast cancer, and the bone is the most common target organ for breast cancer metastasis, followed by the lungs and liver.
Abstract
Purpose: We aimed to investigate organ-specific recurrence or the metastatic pattern of breast cancer according to biological subtypes and clinical characteristics. Methods: We retrospectively analyzed the medical records of 168 patients with recurrent breast cancer who were diagnosed between January 1, 2000 and April 30, 2017. Four biological subtypes were classified according to estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), and Ki-67 expression: luminal A, luminal B, HER2-enriched, and triple negative breast cancer (TNBC). To analyze recurrence patterns according to biological subtypes, we accessed clinical variables including age at diagnosis, TNM stage, type of surgery in the breast and axilla, histologic grade, nuclear grade, lymphatic, vascular, and neural invasion, Ki-67 expression and recurrence to distant organs. Results: The biological subtypes of recurrent breast cancer comprised the following luminal A (n=33, 19.6%), luminal B (n=95, 56.5%), HER2 enriched (n=19, 11.3%), and TNBC (n=21, 12.5%). Luminal A (7.7%) and B (6.5%) subtypes were associated with the increased rate of local recurrence compared to HER2-enriched (2.4%) and TNBC subtypes (1.8%) (p=0.005). The bone (53.6%) was the most common metastatic organ, followed by the lung (34.5%), liver (29.8%), brain (17.9%), and other visceral organ (7.7%). Bone metastasis was commonly observed in individuals with luminal B (63.2%), HER2-enriched (57.9%), and luminal A (42.4%) subtypes (p=0.005). Most liver metastases occur in individuals with luminal B (40.0%) and HER2-enriched subtypes (31.6%) (p=0.002). Conclusion: Luminal B subtype was commonly observed in individuals with recurrent breast cancer, and the bone is the most common target organ for breast cancer metastasis, followed by the lungs and liver.
참고문헌 (29)
- Prat A, "Clinical implications of the intrinsic molecular subtypes of breast cancer", Breast, 24(Suppl 2), pp.S26~S35 (2015)
- Prat A, "Deconstructing the molecular portraits of breast cancer", Mol Oncol, 5, pp.5~23 (2011)
- Goldhirsch A, "Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013", Ann Oncol, 24, pp.2206~2223 (2013)
- Howlader N, "US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status", J Natl Cancer Inst, 106 (2014)
- Althuis MD, "Etiology of hormone receptor-defined breast cancer: a systematic review of the literature", Cancer Epidemiol Biomarkers Prev, 13, pp.1558~1568 (2004)
- Perou CM, "Molecular portraits of human breast tumours", Nature, 406, pp.747~752 (2000)
- Norton L, "Is cancer a disease of self-seeding?", Nat Med, 12, pp.875~878 (2006)
- Paget S, "The distribution of secondary growths in cancer of the breast", Cancer Metastasis Rev, 8, pp.98~101 (1989)
- Lin NU, "CNS metastases in breast cancer", J Clin Oncol, 22, pp.3608~3617 (2004)
- Minn AJ, "Genes that mediate breast cancer metastasis to lung", Nature, 436, pp.518~524 (2005)
- Clayton AJ, "Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer", Br J Cancer, 91, pp.639~643 (2004)
- Kennecke H, "Risk of early recurrence among postmenopausal women with estrogen receptor-positive early breast cancer treated with adjuvant tamoxifen", Cancer, 112, pp.1437~1444 (2008)
- Miller KD, "Occult central nervous system involvement in patients with metastatic breast cancer: prevalence, predictive factors and impact on overall survival", Ann Oncol, 14, pp.1072~1077 (2003)
- Alanko A, "Significance of estrogen and progesterone receptors, disease-free interval, and site of first metastasis on survival of breast cancer patients", Cancer, 56, pp.1696~1700 (1985)
- Hess KR, "Estrogen receptors and distinct patterns of breast cancer relapse", Breast Cancer Res Treat, 78, pp.105~118 (2003)
- Smid M, "Subtypes of breast cancer show preferential site of relapse", Cancer Res, 68, pp.3108~3114 (2008)
- Han-Sung Kim, "Analysis of the Potent Prognostic Factors in Luminal-Type Breast Cancer", Journal of Breast Cancer, 15(4), pp.401~406 (2012), 한국유방암학회[DOI]
- Bustreo S, "Optimal Ki67 cut-off for luminal breast cancer prognostic evaluation: a large case series study with a long-term follow-up", Breast Cancer Res Treat, 157, pp.363~371 (2016)
- 박경미, "Silver-Enhanced In Situ Hybridization as an Alternative to Fluorescence In Situ Hybridization for Assaying HER2 Amplification in Clinical Breast Cancer", Journal of Breast Cancer, 14(4), pp.276~282 (2011), 한국유방암학회
- Kennecke H, "Metastatic behavior of breast cancer subtypes", J Clin Oncol, 28, pp.3271~3277 (2010)
- Saphner T, "Annual hazard rates of recurrence for breast cancer after primary therapy", J Clin Oncol, 14, pp.2738~2746 (1996)
- Ignatov A, "Patterns of breast cancer relapse in accordance to biological subtype", J Cancer Res Clin Oncol, 144, pp.1347~1355 (2018)
- Metzger-Filho O, "Patterns of Recurrence and outcome according to breast cancer subtypes in lymph node-negative disease: results from international breast cancer study group trials VIII and IX", J Clin Oncol, 31, pp.3083~3090 (2013)
- Cossetti RJ, "Comparison of breast cancer recurrence and outcome patterns between patients treated from 1986 to 1992 and from 2004 to 2008", J Clin Oncol, 33, pp.65~73 (2015)
- Voduc KD, "Breast cancer subtypes and the risk of local and regional relapse", J Clin Oncol, 28, pp.1684~1691 (2010)
- Colleoni M, "Annual hazard rates of recurrence for breast cancer during 24 years of follow-up: results from the international breast cancer study group trials I to V", J Clin Oncol, 34, pp.927~935 (2016)
- Gong Y, "Impact of molecular subtypes on metastatic breast cancer patients: a SEER population-based study", Sci Rep, 7, pp.45411~ (2017)
- Wu X, "Pattern of local recurrence and distant metastasis in breast cancer by molecular subtype", Cureus, 8, pp.e924~ (2016)
- Nguyen PL, "Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy", J Clin Oncol, 26, pp.2373~2378 (2008)